Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective

Aisling Barry; Smith Apisarnthanarax; Grainne M O'Kane; Gonzalo Sapisochin; Robert Beecroft; Riad Salem; Sang Min Yoon; Young-Suk Lim; John Bridgewater; Brian Davidson; Marta Scorsetti; Luigi Solbiati; Adam Diehl; Pablo Munoz Schuffenegger; Jonathan G Sham; David Cavallucci; Zita Galvin; Laura A Dawson; Maria A Hawkins

doi:10.1016/S2468-1253(20)30182-5

Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective

Aisling Barry, Smith Apisarnthanarax, Grainne M O'Kane, Gonzalo Sapisochin, Robert Beecroft, Riad Salem, Sang Min Yoon, Young-Suk Lim, John Bridgewater, Brian Davidson, Marta Scorsetti, Luigi Solbiati, Adam Diehl, Pablo Munoz Schuffenegger, Jonathan G Sham, David Cavallucci, Zita Galvin, Laura A Dawson, Maria A Hawkins

Istituto Clinico Humanitas

Research output: Contribution to journal › Review article › peer-review

Abstract

Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.

Original language	English
Pages (from-to)	765-775
Number of pages	11
Journal	The Lancet Gastroenterology and Hepatology
Volume	5
Issue number	8
DOIs	https://doi.org/10.1016/S2468-1253(20)30182-5
Publication status	Published - Aug 2020

Keywords

Betacoronavirus
Bile Duct Neoplasms/therapy
COVID-19
Carcinoma, Hepatocellular/pathology
Cholangiocarcinoma/therapy
Clinical Decision-Making
Coronavirus Infections/epidemiology
Humans
Liver Neoplasms/pathology
Neoplasm Staging
Pandemics
Patient Care Team
Pneumonia, Viral/epidemiology
Risk Factors
SARS-CoV-2

Access to Document

10.1016/S2468-1253(20)30182-5

Fingerprint Dive into the research topics of 'Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective'. Together they form a unique fingerprint.

Cite this

Barry, A., Apisarnthanarax, S., O'Kane, G. M., Sapisochin, G., Beecroft, R., Salem, R., Yoon, S. M., Lim, Y-S., Bridgewater, J., Davidson, B., Scorsetti, M., Solbiati, L., Diehl, A., Schuffenegger, P. M., Sham, J. G., Cavallucci, D., Galvin, Z., Dawson, L. A., & Hawkins, M. A. (2020). Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. The Lancet Gastroenterology and Hepatology, 5(8), 765-775. https://doi.org/10.1016/S2468-1253(20)30182-5

Management of primary hepatic malignancies during the COVID-19 pandemic : recommendations for risk mitigation from a multidisciplinary perspective. / Barry, Aisling; Apisarnthanarax, Smith; O'Kane, Grainne M; Sapisochin, Gonzalo; Beecroft, Robert; Salem, Riad; Yoon, Sang Min; Lim, Young-Suk; Bridgewater, John; Davidson, Brian; Scorsetti, Marta ; Solbiati, Luigi; Diehl, Adam; Schuffenegger, Pablo Munoz; Sham, Jonathan G; Cavallucci, David; Galvin, Zita; Dawson, Laura A; Hawkins, Maria A.

In: The Lancet Gastroenterology and Hepatology, Vol. 5, No. 8, 08.2020, p. 765-775.

Research output: Contribution to journal › Review article › peer-review

Barry, A, Apisarnthanarax, S, O'Kane, GM, Sapisochin, G, Beecroft, R, Salem, R, Yoon, SM, Lim, Y-S, Bridgewater, J, Davidson, B, Scorsetti, M , Solbiati, L, Diehl, A, Schuffenegger, PM, Sham, JG, Cavallucci, D, Galvin, Z, Dawson, LA & Hawkins, MA 2020, 'Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective', The Lancet Gastroenterology and Hepatology, vol. 5, no. 8, pp. 765-775. https://doi.org/10.1016/S2468-1253(20)30182-5

Barry, Aisling ; Apisarnthanarax, Smith ; O'Kane, Grainne M ; Sapisochin, Gonzalo ; Beecroft, Robert ; Salem, Riad ; Yoon, Sang Min ; Lim, Young-Suk ; Bridgewater, John ; Davidson, Brian ; Scorsetti, Marta ; Solbiati, Luigi ; Diehl, Adam ; Schuffenegger, Pablo Munoz ; Sham, Jonathan G ; Cavallucci, David ; Galvin, Zita ; Dawson, Laura A ; Hawkins, Maria A. / Management of primary hepatic malignancies during the COVID-19 pandemic : recommendations for risk mitigation from a multidisciplinary perspective. In: The Lancet Gastroenterology and Hepatology. 2020 ; Vol. 5, No. 8. pp. 765-775.

@article{dea80089b81b49eaa152d2d131e54f0d,

title = "Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective",

abstract = "Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.",

keywords = "Betacoronavirus, Bile Duct Neoplasms/therapy, COVID-19, Carcinoma, Hepatocellular/pathology, Cholangiocarcinoma/therapy, Clinical Decision-Making, Coronavirus Infections/epidemiology, Humans, Liver Neoplasms/pathology, Neoplasm Staging, Pandemics, Patient Care Team, Pneumonia, Viral/epidemiology, Risk Factors, SARS-CoV-2",

author = "Aisling Barry and Smith Apisarnthanarax and O'Kane, {Grainne M} and Gonzalo Sapisochin and Robert Beecroft and Riad Salem and Yoon, {Sang Min} and Young-Suk Lim and John Bridgewater and Brian Davidson and Marta Scorsetti and Luigi Solbiati and Adam Diehl and Schuffenegger, {Pablo Munoz} and Sham, {Jonathan G} and David Cavallucci and Zita Galvin and Dawson, {Laura A} and Hawkins, {Maria A}",

year = "2020",

month = aug,

doi = "10.1016/S2468-1253(20)30182-5",

language = "English",

volume = "5",

pages = "765--775",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier Ltd",

number = "8",

}

TY - JOUR

T1 - Management of primary hepatic malignancies during the COVID-19 pandemic

T2 - recommendations for risk mitigation from a multidisciplinary perspective

AU - Barry, Aisling

AU - Apisarnthanarax, Smith

AU - O'Kane, Grainne M

AU - Sapisochin, Gonzalo

AU - Beecroft, Robert

AU - Salem, Riad

AU - Yoon, Sang Min

AU - Lim, Young-Suk

AU - Bridgewater, John

AU - Davidson, Brian

AU - Scorsetti, Marta

AU - Solbiati, Luigi

AU - Diehl, Adam

AU - Schuffenegger, Pablo Munoz

AU - Sham, Jonathan G

AU - Cavallucci, David

AU - Galvin, Zita

AU - Dawson, Laura A

AU - Hawkins, Maria A

PY - 2020/8

Y1 - 2020/8

N2 - Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.

AB - Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.

KW - Betacoronavirus

KW - Bile Duct Neoplasms/therapy

KW - COVID-19

KW - Carcinoma, Hepatocellular/pathology

KW - Cholangiocarcinoma/therapy

KW - Clinical Decision-Making

KW - Coronavirus Infections/epidemiology

KW - Humans

KW - Liver Neoplasms/pathology

KW - Neoplasm Staging

KW - Pandemics

KW - Patient Care Team

KW - Pneumonia, Viral/epidemiology

KW - Risk Factors

KW - SARS-CoV-2

U2 - 10.1016/S2468-1253(20)30182-5

DO - 10.1016/S2468-1253(20)30182-5

M3 - Review article

C2 - 32511951

VL - 5

SP - 765

EP - 775

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

SN - 2468-1253

IS - 8

ER -